This study is a multicenter, non-interventional, retrospective, medical chart review of participants with metastatic renal cell cancer(mRCC) treated with avelumab plus axitinib as a first-line therapy in Japan between 20 December 2019 and 17 October 2022. All decisions regarding clinical management and treatment of the participating patients were made by the investigator as part of standard care in real-world clinical setting and were not contingent upon the patient's participation in the study. Data will be collected if available per study site.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Age of Participants at Baseline
Timeframe: At Baseline (prior to initial treatment with avelumab plus axitinib)
Height of Participants at Baseline
Timeframe: At Baseline (prior to initial treatment with avelumab plus axitinib)
Body Weight of Participants at Baseline
Timeframe: At Baseline (prior to initial treatment with avelumab plus axitinib)
Body Mass Index of Participants at Baseline
Timeframe: At Baseline (prior to initial treatment with avelumab plus axitinib)
C-Reactive Protein Levels of Participants at Baseline
Timeframe: At Baseline (prior to initial treatment with avelumab plus axitinib)
Estimated Glomerular Filtration Rate of Participants at Baseline
Timeframe: At Baseline (prior to initial treatment with avelumab plus axitinib)
Smoking History Status of Participants at Baseline
Timeframe: At Baseline (prior to initial treatment with avelumab plus axitinib)
Eastern Cooperative Oncology Group (ECOG) Performance Scale Score Status of Participants at Baseline
Timeframe: At Baseline (prior to initial treatment with avelumab plus axitinib)
Number of Participants With Metastatic Organs at Baseline
Timeframe: At Baseline (prior to initial treatment with avelumab plus axitinib)
Invasion Depth (T Factor) of Participants at Baseline
Timeframe: At Baseline (prior to initial treatment with avelumab plus axitinib)
Lymph Node Metastasis (N Factor) Status of Participants at Baseline
Timeframe: At Baseline (prior to initial treatment with avelumab plus axitinib)
Distant Metastasis (M Factor) Status of Participants at Baseline
Timeframe: At Baseline (prior to initial treatment with avelumab plus axitinib)
Tumor Histological Type of Participants at Baseline
Timeframe: At Baseline (prior to initial treatment with avelumab plus axitinib)
Number of Participants With Presence or Absence of Sarcomatoid Component in Participants at Baseline
Timeframe: At Baseline (prior to initial treatment with avelumab plus axitinib)
Fuhrman Grade Status of Participants at Baseline
Timeframe: At Baseline (prior to initial treatment with avelumab plus axitinib)
Availability of Proteinuria in Participants at Baseline
Timeframe: At Baseline (prior to initial treatment with avelumab plus axitinib)
Performance of Nephrectomy in Participants
Timeframe: At Baseline (prior to initial treatment with avelumab plus axitinib)
Number of Participants With Presence or Absence of Clinically Important Comorbidities of Participants at Baseline
Timeframe: At Baseline (prior to initial treatment with avelumab plus axitinib)
Number of Participants With Presence or Absence of Clinically Important Concomitant Drugs in Participants at Baseline
Timeframe: At Baseline (prior to initial treatment with avelumab plus axitinib)
Number of Participants With Initiation of Systemic Therapy Within One Year of Diagnosis
Timeframe: At Baseline (prior to initial treatment with avelumab plus axitinib)
Number of Participants With Karnofsky Performance Status Less Than (<) 80 Percent (%) at Baseline
Timeframe: At Baseline (prior to initial treatment with avelumab plus axitinib)
Number of Participants With Hemoglobin Value Below the Lower Normal Limit at Baseline
Timeframe: At Baseline (prior to initial treatment with avelumab plus axitinib)
Number of Participants With Corrected Calcium Value Above the Upper Normal Limit in Participants at Baseline
Timeframe: At Baseline (prior to initial treatment with avelumab plus axitinib)
Number of Participants With Neutrophil Count Above the Upper Normal Limit in Participants at Baseline
Timeframe: At Baseline (prior to initial treatment with avelumab plus axitinib)
International Metastatic RCC Database Consortium (IMDC) Risk Group in Participants at Baseline
Timeframe: At Baseline (prior to initial treatment with avelumab plus axitinib)
Number of Risk Factors in Participants at Baseline
Timeframe: At Baseline (prior to initial treatment with avelumab plus axitinib)